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Abstract
Resting-state EEG microstates are brief (50–100 ms) periods, in which the spatial configuration of scalp global field
power remains quasi-stable before rapidly shifting to another configuration. Changes in microstate parameters have
been described in patients with psychotic disorders. These changes have also been observed in individuals with a
clinical or genetic high risk, suggesting potential usefulness of EEG microstates as a biomarker for psychotic disorders.
The present study aimed to investigate the potential of EEG microstates as biomarkers for psychotic disorders and
future transition to psychosis in patients at ultra-high-risk (UHR). We used 19-channel clinical EEG recordings and
orthogonal contrasts to compare temporal parameters of four normative microstate classes (A–D) between patients
with first-episode psychosis (FEP; n= 29), UHR patients with (UHR-T; n= 20) and without (UHR-NT; n= 34) later
transition to psychosis, and healthy controls (HC; n= 25). Microstate A was increased in patients (FEP & UHR-T & UHR-
NT) compared to HC, suggesting an unspecific state biomarker of general psychopathology. Microstate B displayed a
decrease in FEP compared to both UHR patient groups, and thus may represent a state biomarker specific to psychotic
illness progression. Microstate D was significantly decreased in UHR-T compared to UHR-NT, suggesting its potential as
a selective biomarker of future transition in UHR patients.
Introduction
Psychotic disorders are complex and debilitating mental
illnesses, affecting multiple domains of everyday life with
potential for chronic outcomes1. However, timely treat-
ment in the early stages of the illness can substantially
improve clinical and functional outcomes2,3. Among
patients with psychotic disorders, it has long been
observed that a prodromal phase may precede the onset of
first psychotic symptoms by several years4. Based on this
observation, operationalized clinical criteria were devel-
oped to detect individuals at risk for psychotic disorders.
The most prevalent among them are the ultra-high-risk
(UHR) criteria, consisting of the presence of either (a)
attenuated positive symptoms; (b) brief limited psychotic
symptoms; or (c) genetic vulnerability accompanied by
functional decline5,6. About 22–29% of UHR patients will
transition to psychosis, with most transitions occurring in
the first 3 years following diagnosis7,8. To optimize tran-
sition prediction, and thereby treatment in UHR patients,
a large body of research has been devoted to identifying
biomarkers that may be used to improve predictive
accuracy9–11.
Reliable biomarkers have adequate discriminatory
capacity, are present at a sufficiently early (ideally pre-
clinical) illness stage, are selective for an illness, and are
reproducible across different patient samples12. Moreover,
to improve clinical applicability, biomarkers need to incur
reasonable costs and minimal patient discomfort. One
method that offers several advantages in biomarker
research is resting-state electroencephalography (EEG).
Apart from being inexpensive and easy to implement,
resting-state EEG can capture the fast-changing dynamics
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of neuronal networks with high temporal resolution.
Studying these networks is extremely relevant in psy-
chosis and UHR research since multiple studies have
demonstrated altered network properties in affected
individuals13–15.
A compelling tool for studying the temporal dynamics
of (eyes-closed) resting-state brain networks are EEG
microstates. EEG microstates are brief (about 50–100 ms)
periods in which the spatial configuration of scalp global
field power remains quasi-stable before rapidly shifting to
another configuration16,17. These spatial configurations
can be clustered into a pre-defined number of config-
urations or classes. Four common classes, labeled A, B, C
and D, explain 65–84% of EEG data variance17. These
classes are present across different sex and age
groups,18,19 different neuropsychiatric diseases20, and
show cross-method consistency and high test–retest
reliability21. Simultaneous functional magnetic resonance
imaging (fMRI)-EEG studies have linked microstate clas-
ses to specific resting-state functional networks22,23.
Microstate classes can be characterized by a set of
temporal parameters: coverage, duration, and occurrence.
Previous research has identified several differences in
these temporal parameters between medication-naïve
patients with schizophrenia and healthy controls24–29.
While these studies have reported changes across all
microstate classes, recent meta-analyses only reported
increased occurrence of microstate C and decreased
duration of microstate D in patients with psychotic dis-
orders30,31. Although less pronounced, some of these
changes are already present in individuals with a clinical
or genetic high risk for schizophrenia32,33, indicating that
microstate alterations already occur at an early stage of
psychotic disorders. The above findings suggest that EEG
resting-state microstates might be a valuable candidate
biomarker for the prediction of psychotic transition in
UHR patients. However, no studies have yet assessed
microstates in UHR patients with respect to future tran-
sition to psychosis.
The present study aimed to investigate microstate
dynamics with respect to their suitability as biomarker for
psychosis and transition to psychosis. To this end, we
included UHR patients with and without a future psy-
chotic transition (UHR-T and UHR-NT, respectively),
first-episode-psychosis (FEP) patients and healthy con-
trols (HC). Our comparisons were set out to examine
state differences unspecific for illness progression (by
comparing FEP, UHR-T, and UHR-NT to HC), state
differences selective for developed psychosis (by com-
paring FEP to UHR-T and UHR-NT), and trait differences
that reflect later transition to psychosis (UHR-T vs. UHR-
NT). Based on previous studies that report microstate
changes in patients with (high risk for) psychotic dis-
orders, we expected to find both state and trait differences
using EEG microstates, thereby showing the potential of
EEG microstates as biomarker.
Methods
The data presented here were collected in the context of
the FePsy (Früherkennung von Psychosen; Early Detection
of Psychoses) project, which was conducted from 2000 to
2017 with the aim to improve early detection of psychosis.
The FePsy project was approved by the local ethics
committee and in accordance with the Declaration of
Helsinki. A detailed description of the project can be
found elsewhere34.
Participants
Patients were help-seeking consecutive referrals to the
FePsy clinic at the psychiatric outpatient department of
the University Psychiatric Clinics (UPK) Basel. Healthy
controls (HC) were recruited from the same geographical
area as the FEP and UHR groups. All participants gave
written informed consent for participation in the project.
FEP and UHR status was determined based on the Basel
Screening Instrument for Psychosis (BSIP)35. Participants
were assigned to the FEP or UHR groups according to the
respective criteria set by Yung et al.36. UHR participants
were followed-up at regular intervals to identify those who
later transitioned to psychosis (UHR-T) and those who
did not (UHR-NT). The definition of transition to psy-
chosis was made using the Brief Psychiatric Rating Scale
(BPRS)37 according to the criteria set by Yung et al.36.
Assessments for transition were performed monthly in
the first year of follow-up, every 3 months in the 2nd and
3rd year, and yearly in the following years. The minimal
follow-up duration before assigning a patient to the UHR-
NT group was 3 years.
Exclusion criteria for patients were age <18 years,
insufficient knowledge of German, IQ < 70, serious med-
ical or surgical illness, previous episode of psychosis due
to substance abuse, and psychotic symptomatology within
a clearly diagnosed affective or borderline personality
disorder. For the present analysis, we additionally exclu-
ded patients with UHR status based solely on BSIP
unspecific criteria (as these criteria are associated with a
lower risk of transition than the UHR criteria38), as well as
all patients who had received antipsychotic treatment
prior to the EEG recording. For healthy controls, exclu-
sion criteria were age <18 years, current or past psychia-
tric disorder, family history of any psychiatric disorder,
head trauma, neurological illness, serious medical or
surgical illness, or substance abuse.
EEG recording and pre-processing
Clinical EEG (20 min) was recorded by a trained lab
assistant while participants were comfortably seated in a
quiet room. The first 8 min of the recording, which
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correspond to resting-state eyes-closed EEG, were used in
the present study. Every 3 min, participants were asked to
briefly open their eyes for 6 s to avoid drowsiness. Addi-
tionally, participants were asked to open their eyes when
behavioral (e.g., relaxation of face and neck muscles) and/
or EEG signs of drowsiness (e.g., slow rolling eye move-
ments, alpha drop-out, increased beta or theta activity)
were observed. EEG was recorded with 19 gold cup
electrodes (Nicolet Biomedical, Inc.), referenced to linked
ears and attached according to the International
10–20 system. Impedances were always kept below 5 kΩ
and sampling rate was 256 Hz.
Offline pre-processing was performed with Brain Vision
Analyzer (Version 2.0, Brain Products GmbH, Munich,
Germany). Raw EEG data were filtered with a bandpass
(IIR; 0.5–70 Hz) and a notch (50 Hz) filter. Eyes-open
epochs were removed based on marker positions and
epochs with severe artefacts due to movement or poor
signal were removed upon visual inspection. Channels
with severe artefacts across the whole recording were
interpolated. Ocular muscle artefacts were removed by
means of Extended Infomax ICA. Subsequently, data were
divided into 2 s segments and segments with residual
artefacts were removed by means of visual inspection
based on consensus between at least two independent
reviewers. Finally, the data were re-referenced to the
common average reference and bandpass filtered (FIR;
2–20 Hz).
Microstate analysis
Microstate analysis was performed with the Microstate
Analysis plug-in (Version 0.3; http://www.thomaskoenig.
ch/Download/EEGLAB_Microstates/) for EEGLAB39 in
Matlab 2015b. Individual microstate maps for each par-
ticipant were calculated from original momentary maps
using Atomize-Agglomerate Hierarchical Clustering
(AAHC)40. The number of clusters was pre-set to four
because four microstate classes have been reported to
explain a large part of EEG data variance in healthy
subjects17 and for comparability with previous studies in
patients with psychotic disorders. Group model maps
were calculated separately for each participant group (HC,
UHR-NT, UHR-T, FEP) using a permutation algorithm
that minimized common variance across subjects26 and
class-labeled into microstates A–D by using minimal
Global Map Dissimilarity and model map norms from
Koenig et al.18. The class-labeled group model maps were
then used as templates to assign individual microstate
maps to the four class-labeled group maps. The micro-
state toolbox ignores the first and last segments and
thereby only calculates non-truncated microstate para-
meters. The following parameters were extracted from
microstate data: coverage (percentage of analysis time
covered by the microstates of a given class), duration (the
average duration of a microstate class in milliseconds),
and occurrence/second (total number of the microstate of
a given class per second).
Statistical analysis
Group differences for each microstate parameter were
investigated by means of separate 4 (microstate class) × 4
(group) repeated measures analysis of variances (ANO-
VAs). Since the goal of the present study was to investi-
gate microstate dynamics with respect to their suitability
as biomarker for psychosis and transition to psychosis, we
carried out specific contrasts. The contrasts were planned
in an orthogonal manner in that a group once split off was
not brought back into a next contrast (Table 1). By
comparing FEP & UHR-T & UHR-NT vs. HC (i.e., all
patient groups combined compared to healthy controls),
contrast I assessed changes in microstates that might
reflect general illness state irrespective of diagnosis.
Contrast II compared FEP vs. combined UHR-T & UHR-
NT, thereby assessing state markers of established psy-
chosis. The last contrast (contrast III) was set to examine
differences that might be predictive of later transition to
psychosis (UHR-T vs. UHR-NT).
All analyses were carried out using SPSS 25. Statistical
tests in the present study are two-sided tests wherever
applicable and the statistical level was set at α= 0.05.
Comparisons of class topography
A challenge in microstate analyses is that the class
topographies used for the assignment of individual
momentary maps and extraction of temporal character-
istics may systematically differ between groups. To assess
for such group differences in microstate class topo-
graphies, we used the Matlab tool Ragu (downloaded from
www.thomaskoenig.ch/Ragu_src.zip41) to perform topo-
graphic analysis of variance (TANOVA). TANOVA uses
the global field power of difference maps and non-
parametric randomization statistics to quantify and assess
between-group differences in scalp topography. Separate
TANOVAs (5000 randomizations, L2-norm normal-
ization of scalp field variance across sensors) were carried
out for each contrast and results were Bonferroni-
corrected for the total number of microstates (n= 4).
Table 1 Orthogonal contrasts.
Contrast Group 1 Group 2
I FEP, UHR-T, UHR-NT vs. HC
II FEP vs. UHR-T, UHR-NT
III UHR-T vs. UHR-NT
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Vigilance
During eyes-closed resting-state conditions, it is possi-
ble that participants exhibit changes in arousal especially
when participant groups are different clinical populations
with some of them medicated. We therefore carried out
an analysis assessing different stages of vigilance. We used
VIGALL 2.0 (downloaded from https://research.uni-
leipzig.de/vigall/) as add-in in Brain Vision Analyzer.
For each participant, alpha center frequency was detected,
as well as adaptations of absolute power thresholds. The
different vigilance stages are: states A (1–3; alertness,
relaxed wakefulness), state B (1–2/3; drowsiness), and
state C (sleep) (see also Olbrich et al.42). Each 1-s segment
was assigned to one of the states. For each state, the
relative number of segments was calculated.
Subsidiary analyses: age mediation and moderation
As reported further below (see “Results”), between-
group comparisons at baseline indicated significant dif-
ferences in age between groups, with FEP being the oldest
group (Table 2). As microstate parameters have been
reported to variate with age18, we investigated whether
age mediated or moderated the significant planned con-
trasts. The age mediation and moderation analyses were
carried out using the PROCESS macro version 3.1 for
SPSS43.
Results
Group characteristics
From a total of 162 participants with available EEG data
initially recruited in the project, 53 participants were
excluded ex post facto due to antipsychotic medication
criteria (n= 18), definition of risk state based on other
criteria than UHR criteria (n= 8), insufficient EEG quality
(n= 24), insufficient follow-up time, or missing informa-
tion on diagnosis (n= 3). A total of 108 participants were
thus included in the analysis, consisting of 29 patients
with first-episode psychosis (FEP), 20 ultra-high-risk
(UHR) patients with (UHR-T) and 34 UHR patients
without (UHR-NT) later transition to psychosis, and 25
healthy controls (HC). Table 2 displays group character-
istics on the four study groups.
Microstate parameters: overall results
Class-labeled group model maps were calculated sepa-
rately for each participant group and are shown in Fig. 1.
The average global explained variance for all groups was
77% and did not significantly differ between groups (F(3,
107) = 1.293, p= 0.281, η2 = 0.036) (Table 2).
Table 2 Sample demographics.
HC UHR-NT UHR-T FEP
n= 25 n= 34 n= 20 n= 29 F/χ2 p Post-hoc
Sex (M:F) 12:13 26:8 11:9 19:10 5.69 0.128
Age (mean [SD]) 22.39 (5.24) 25.32 (8.14) 25.80 (7.20) 28.68 (7.64) 3.41 0.020 FEP > HC
BPRS (mean [SD])
Total score – 41.62 (11.70) 41.84 (9.67) 53.81 (11.02) 10.60 <0.001 FEP > UHR-T, UHR-NT
Depression/anxiety – 9.59 (4.32) 10.69 (2.87) 11.79 (4.44) 2.09 0.131
Psychosis/thought disturbance – 6.30 (2.35) 6.52 (2.12) 12.09 (3.42) 38.68 <0.001 FEP > UHR-T, UHR-NT
Negative symptoms – 6.43 (2.51) 5.76 (2.70) 5.75 (2.81) 0.58 0.562
Activation – 5.80 (2.38) 5.22 (1.46) 7.21 (3.55) 3.34 0.041 FEP > UHR-T
Comorbidities (ICD-10)
F10–F19a – 1 3 1
F30–F39a – 9 16 7
F40–F49a – 3 9 0
F60–F69a – 0 0 1
EEG total analysis time (mean [SD]) 299.72 (41.16) 296.74 (48.57) 309.35 (48.14) 296.71 (45.24) 0.38 0.768
EEG explained variance (%) (mean [SD]) 76.92 (2.77) 76.75 (2.95) 75.42 (4.00) 77.25 (3.68) 1.29 0.281
HC healthy controls, UHR-NT ultra-high-risk without transition to psychosis at follow-up, UHR-T ultra-high-risk with transition to psychosis at follow-up, FEP first-episode
psychosis, BPRS Brief Psychiatric Rating Scale, SD standard deviation.
aF10–F19=Mental and behavioral disorders due to psychoactive substance use; F30–F39=Mood [affective] disorders; F40–F49= Neurotic, stress-related, and
somatoform disorders; F60–F69= Disorders of adult personality and behavior. Significance level is 0.05; only significant differences between groups (Games-Howell
corrected) are presented for post-hoc comparisons.
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Microstate parameters: between-group differences
We found significant class x group interactions for all
microstate parameters: coverage (F(8.291, 287.434)=
4.186, p < 0.001, η2 = 0.108); duration (F(7.280, 252.370)=
2.130, p= 0.039, η2 = 0.058); and occurrence (F(8.671,
300.603)= 6.334, p < 0.001, η2 = 0.154). We next per-
formed separate one-way ANOVAs to further investigate
group differences in specific microstate classes. These
follow-up tests revealed significant between-group dif-
ferences for microstate A coverage (F(3, 107)= 10.582,
p < 0.001, η2 = 0.234), duration (F(3, 107)= 4.305, p=
0.007, η2 = 0.110) and occurrence (F(3, 107)= 6.149, p=
0.001, η2 = 0.151), microstate B occurrence (F(3, 107)=
2.756, p= 0.046, η2 = 0.740), and microstate D coverage
(F(3, 107)= 3.561, p= 0.017, η2 = 0.093) and occurrence
(F(3, 107)= 5.980, p= 0.001, η2 = 0.147). There were no
significant results for microstate C. Table 3 displays
means for all microstate parameters.
Microstate parameters: planned contrasts
By comparing FEP & UHR-T & UHR-NT vs. HC (i.e., all
patient groups combined compared to healthy controls),
contrast I assessed changes in microstates that might reflect
general illness state irrespective of diagnosis. We found a
significant increase of microstate A coverage (t(104)=
2.889, p= 0.005, d= 0.580) and occurrence (t(104)= 2.390,
p= 0.019, d= 0.514) in all patient groups compared to HC.
In order to specifically assess state markers of estab-
lished psychosis, we compared FEP vs. combined UHR-T
& UHR-NT (contrast II). FEP showed significantly
increased microstate A coverage (t(104)= 4.239, p <
0.001, d= 1.006), duration (t(104)= 2.509, p= 0.014, d=
0.605) and occurrence (t(104)= 3.293, p= 0.001, d=
0.814) compared to the two UHR groups. In addition, we
observed significantly decreased microstate B coverage
(t(104)=−2.484, p= 0.015, d=−0.557) and occurrence
(t(104)=−2.671, p= 0.009, d=−0.632) in FEP com-
pared to UHR-T and UHR-NT combined.
The last contrast (contrast III) was set to examine dif-
ferences that might be predictive of later transition to
psychosis (UHR-T vs. UHR-NT). The UHR-T group
showed significantly decreased microstate D coverage
(t(104)=−3.043, p= 0.003, d=−0.840) and occurrence
(t(104)=−4.109, p < 0.001, d=−1.244) compared to
UHR-NT.
Topographic analysis of variance (TANOVA)
Contrast I
The TANOVA group main effect was significant (p=
0.001); significant differences in topography were
observed in microstates A (p= 0.006), B (p= 0.02), and D
(p= 0.002), while the group effect for microstate C was
non-significant (p= 0.19).
Contrast II
The TANOVA group main effect was significant (p=
0.04); differences in topography reached marginal sig-
nificance in the case of microstate D (p= 0.05), while they
Fig. 1 Spatial configuration of the four microstate classes. Each row displays the four topographic configurations (A-D) for each group. HC
healthy controls, UHR-NT ultra-high-risk without transition, UHR-T ultra-high-risk with transition, FEP first-episode psychosis.
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were non-significant for microstates A (p= 0.50), B (p=
0.08), and C (p= 1.0).
Contrast III
The TANOVA group main effect was significant (p=
0.007); significant differences in topography were
observed for microstates B (p= 0.02) and C at a trend
level (p= 0.06), while the group effect was non-significant
for microstates A (p= 0.14) and D (p= 0.11).
Vigilance
On average, participants spent 71% in state A (awake),
and 29% in state B (drowsiness). No significant interaction
(group x state) (F(15, 624)= 0.471, p= 0.955) or main
effect of group (F(3, 624)= 0.000, p= 1.000) was
observed.
Subsidiary analyses: age mediation and moderation
In the mediation analysis, there was no significant
mediation effect of age in any of the previously significant
contrasts. In moderation analyses, significant interactions
between age and group were observed for microstate A
contribution (F(1,104)= 4.132, p= 0.045) in contrast I
(FEP & UHR-T & UHR-NT vs. HC). More specifically,
this microstate parameter was increased in the patient
groups FEP & UHR-T & UHR-NT compared to HC, but
only in younger subjects. In addition, there were sig-
nificant age x group interactions for microstate D con-
tribution (F(1, 50)= 8.672, p= 0.005) and occurrence
(F(1, 50)= 4.143, p= 0.047) in contrast III (UHR-T vs.
UHR-NT), with the microstate parameters being
decreased in UHR-T compared to UHR-NT only in
younger subjects. The main effect of group in contrast III
remained significant after controlling for age, while this
was not the case for contrast I. Age did not significantly
moderate contrast II (FEP vs. UHR-T & UHR-NT).
Discussion
The aim of this study was to investigate resting-state
EEG microstates as biomarker for psychotic disorders and
transition to psychosis in high-risk individuals. To this
end, we investigated microstate parameters in patients
with first-episode psychosis (FEP), patients with ultra-
high-risk for psychotic disorders (UHR), and healthy
controls (HC). Moreover, we were able to directly com-
pare EEG microstate parameters in patients with (UHR-
T) and without (UHR-NT) a subsequent transition to
psychosis, which makes this paper unique in EEG
microstate literature.
We found increased microstate A coverage and occur-
rence to differentiate the three patient groups (FEP, UHR-
T, and UHR-NT) from HC, as well as increased micro-
state A coverage, occurrence and duration to differentiate
FEP from the two combined UHR groups. Previous stu-
dies have reported increased microstate A occurrence26,27
and coverage26–28 in schizophrenia patients compared to
controls, but also increased microstate A coverage and
duration in drug-naïve patients with panic disorders
Table 3 Means for all microstate parameters.
HC UHR-NT UHR-T FEP F p Post-hoc
Coverage (%) (mean [SD])
A 22.74 (5.38) 23.27 (5.08) 26.27 (6.14) 30.77 (7.50) 10.58 <0.001 FEP > UHR-NT, HC
B 20.85 (4.32) 21.46 (4.85) 21.11 (7.08) 18.04 (6.26) 2.28 0.084
C 32.23 (6.41) 30.64 (8.64) 34.30 (5.33) 29.18 (9.28) 1.88 0.138
D 24.18 (6.62) 24.63 (7.38) 18.32 (7.73) 22.03 (7.65) 3.56 0.017 UHR-T < UHR-NT, HC
Duration (ms) (mean [SD])
A 66.69 (7.47) 65.49 (7.75) 70.48 (8.95) 73.71 (13.50) 4.30 0.007 FEP > UHR-NT
B 65.12 (13.98) 62.89 (8.81) 63.50 (11.10) 59.58 (11.23) 1.17 0.326
C 77.29 (15.92) 72.94 (19.28) 76.74 (9.16) 70.84 (18.46) 0.88 0.456
D 66.68 (15.19) 64.28 (13.00) 60.82 (14.24) 60.18 (11.55) 1.33 0.268
Occurrence/s (mean [SD])
A 3.47 (0.83) 3.60 (0.67) 3.79 (0.72) 4.29 (0.89) 6.15 0.001 FEP > UHR-NT, HC
B 3.31 (0.59) 3.45 (0.61) 3.34 (0.80) 2.99 (0.60) 2.76 0.046 FEP < UHR-NT
C 4.33 (0.68 4.31 (0.76) 4.60 (0.61) 4.21 (0.88) 1.08 0.361
D 3.69 (0.64) 3.86 (0.69) 2.97 (0.76) 3.68 (0.96) 5.98 0.001 UHR-T > HC, UHR-NT, FEP
Significance level is 0.05; only significant differences between groups (Games-Howell corrected) are presented for post-hoc comparisons.
HC healthy controls, UHR-NT ultra-high-risk without transition, UHR-T ultra-high-risk with transition, FEP first-episode psychosis.
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compared to healthy controls25 and a positive correlation
of microstate A parameters with depression severity44.
Given the high rates of non-psychotic psychiatric
comorbidity in all patient groups (60%; see symptom
profiles presented in Table 2), we suggest that the
observed microstate A parameter increase might repre-
sent an unspecific state marker of general
psychopathology.
Decreased microstate B coverage and occurrence was
found to additionally differentiate FEP from the combined
UHR groups. Decreased microstate B duration has been
consistently reported in unmedicated schizophrenia
patients compared to healthy controls24,27,28 (with a single
exception25). With microstate B successfully differentiat-
ing between FEP and UHR-T & UHR-NT, who at time of
the measurement were experiencing psychosis-like
symptoms but had not (yet) transitioned to psychosis,
these results suggest that microstate B might represent a
state biomarker specific to psychotic illness progression.
Interestingly, previous research by Andreou et al.32 found
differences in the opposite direction between medicated,
stable FEP and high-risk patients with respect to micro-
states A (decreased coverage in FEP) and B (increased
coverage in FEP), suggesting a modulatory role for anti-
psychotic medication on these two microstates and thus
providing support for their view as state markers.
The present study is the first to directly compare UHR-
T to UHR-NT regarding resting-state EEG microstates at
baseline. We found decreased microstate D coverage and
occurrence in UHR-T compared to UHR-NT. In previous
research, decreased microstate D coverage, occurrence
and duration were observed in patients with 22q11 dele-
tion syndrome, a genetic syndrome associated with high
psychosis risk33. Microstate D coverage was also found to
be decreased in unmedicated schizophrenia patients
compared to healthy controls25–27, which was confirmed
by two recent meta-analysis, including medicated and
unmedicated patients with psychotic disorders31.
Dynamics of microstate D were further suggested as
candidate endophenotype by a study that compared
medicated schizophrenia patients and their siblings to
healthy controls and found decreased microstate D in
both the patient group, as well as their siblings30. Our
results expand upon these previous findings, indicating
that decreased microstate D could be a selective trait
marker that potentially predicts later transition to psy-
chosis in UHR patients. This is in line with a previous
suggestion that microstate D is associated with reality
testing due to its reduction in schizophrenia27, hypnosis45,
and sleep46. Further, microstate D was found to have
shortened duration during periods of hallucinations47 and
had increased duration at follow-up for patients that
responded well to antipsychotic medication25. This
function might be mediated by attentional processes, as
microstate D has been associated with the frontoparietal
attention network48, and suggested to be dominant during
focus switching and reorientation of attention22, during
no-task resting49, and involved in error-monitoring47.
Surprisingly, we did not find any microstate C differ-
ences in any of the studied contrasts. Microstate C was
suggested to predominantly occur during activation of the
salience network22, and would have therefore been
expected to be abnormal in patients with psychotic dis-
orders based on the aberrant salience account of psy-
chosis50. On the other hand, although both
aforementioned meta-analyses30,31 reported microstate C
to be increased (coverage and occurrence) in schizo-
phrenia patients, this effect is not very consistent across
single studies, with approximately half of existing studies
reporting differences in this microstate between unme-
dicated schizophrenia patients and healthy controls25,27,28,
while the other half failed to observe significant differ-
ences24,26,29. This inconsistency may be explained by a
recent observation that the optimal number of microstate
maps to describe resting-state EEG data may be higher
than the original four (A–D). Custo et al.48 have proposed
a 7-map model and suggested that microstate C in the
original 4-map model may, in fact, result from two spa-
tially correlated but separate microstate topographies
corresponding to different resting-state networks, which
might explain the above discrepant results across studies.
Further research is warranted to confirm this hypothesis,
as there have not been any studies using the 7-map model
in patients with psychotic disorders so far.
FEP being the oldest participant group might raise the
question whether the significant age difference between
HC and FEP partially accounted for our results. However,
age was not a significant mediator of group differences in
our subsidiary analysis. Interestingly however, differences
in microstate A between HC and patient groups as well as
differences in microstate D between UHR-T and UHR-
NT were more pronounced in younger subjects, thus
revealing age as moderator for these microstates. As
Koenig et al.18 and Tomescu et al.19 demonstrated,
microstate temporal parameters change throughout
developmental stages from early childhood to late adult-
hood. This suggests that microstate differences found in
this study might be influenced by altered maturation
processes in patients compared to healthy controls.
Indeed, recent publications have suggested that UHR
patients exhibit an altered structural maturation process
compared to healthy controls51, which was shown to be
predictive of greater risk of transition to psychosis and
poor functional outcomes only in younger UHR
patients52.
To our knowledge, this is the first study investigating
microstates in patients at high risk for psychotic disorders
under consideration of later transition status. Its strengths
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include (a) the inclusion of only antipsychotic-naïve
patients to ensure sample homogeneity (see Stevens
et al.53 and Yoshimura et al.54 for effects of antipsychotic
medication on microstate parameters), and (b) the fact
that transition status for UHR patients was determined
based on a sufficiently long follow-up time leaning on
reported transition trajectories34,55,56 to minimize the
amount of potential unnoticed late transitions in the
UHR-NT group.
However, certain methodological points should be
considered as well. First, based on previously established
norms by Koenig et al.18, the present study assessed four
microstate classes. As mentioned above, an increased
number of microstates might improve the explained glo-
bal variance17. Nevertheless, using four microstate classes
has the important advantage of allowing direct compar-
isons of our results with previous studies in patients with
psychotic disorders and high psychosis risk. Altogether
with our relatively high global explained variance of 77%,
we deem our current method appropriate. As a second
limitation, it should be kept in mind that different pre-
processing strategies, data selection methods and
smoothing parameters17, as well as differences in micro-
state analysis steps (e.g., the template used for microstate
class assignment21) may influence microstate temporal
parameters. In our study, we chose pre-processing and
analysis parameters such as to ensure maximum com-
parability with a previous study of UHR patients by our
group32 but there may be differences compared to other
studies. For future research in the field of EEG micro-
states, it would be very useful to harmonize methods in
order to promote comparability.
Conclusion
In sum, the present results suggest microstates A and B
as state markers, respectively, for general psychopathology
and psychotic symptoms, and microstate D as a trait
marker that selectively identifies those UHR patients that
make a future transition to psychosis. Overall, the search
for robust biomarkers for transition to psychosis from the
high-risk state is still a key challenge in the field of early
detection research, although multiple variables have been
suggested to increase predictive accuracy57 since the early
starting points of research on prediction of psychosis
transition58 beyond the genetic risk approach59. With the
present study, we demonstrate the potential of EEG
microstates parameters as a valuable biomarker psychosis
transition in the wake of a recently published article that
found microstates to successfully (accuracy 82.7%) dif-
ferentiate between patients with psychotic disorders and
healthy controls60. Further research is warranted to
establish the robustness of these results in order to
enhance predictive accuracy, ideally in a combined mul-
tiple variable approach.
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